Skip to main content
Year archive

STARPHARMA HOLDINGS LIMITED — 2021 filings

All 67 regulatory filings released by STARPHARMA HOLDINGS LIMITED (SPL) in 2021, sourced directly from the official regulator.

67 Filings
2021 Period
2021 filings (67)
Filing Released Lang
Notification of cessation of securities - SPL 4 pages 24.1KB
Regulatory Filings
2021-12-22 English
Shareholder Newsletter 5 pages 1.0MB
Regulatory Filings
2021-12-15 English
VIRALEZE antiviral nasal spray registered in Saudi Arabia 2 pages 240.3KB
Regulatory Filings
2021-12-13 English
VIRALEZE successfully launched in Vietnam 2 pages 216.6KB
Capital/Financing Update
2021-12-12 English
US Biopharma DEP Research Agreement - Additional Information 2 pages 199.5KB
Regulatory Filings
2021-12-07 English
Starpharma signs DEP Research Agreement with US Biopharma Co 2 pages 202.6KB
Regulatory Filings
2021-12-06 English
VIRALEZE distribution agreement and launch in Vietnam 3 pages 225.7KB
Regulatory Filings
2021-12-02 English
Notification regarding unquoted securities - SPL 6 pages 28.0KB
Share Issue/Capital Change
2021-12-02 English
Change in Director's Interest Notice - J Fairley 2 pages 199.4KB
Director's Dealing
2021-12-02 English
VIRALEZE registered in Vietnam with launch this week 3 pages 215.4KB
Regulatory Filings
2021-11-30 English
AGM Chairman address and CEO presentation 41 pages 7.8MB
AGM Information
2021-11-29 English
AGM Results 2 pages 214.5KB
Declaration of Voting Results & Voting Rights Announcements
2021-11-29 English
Positive DEP phase 2 interim results in prostate cancer 5 pages 329.6KB
Interim / Quarterly Report
2021-11-24 English
Jobkeeper s323DB(1) notice 2 pages 212.9KB
Regulatory Filings
2021-11-10 English
Starpharma to present at Bell Potter Healthcare Conference 29 pages 5.9MB
Investor Presentation
2021-11-08 English
Application for quotation of securities - SPL 7 pages 29.1KB
Share Issue/Capital Change
2021-10-31 English
Quarterly Cashflow and Activities Report 7 pages 373.1KB
Interim / Quarterly Report
2021-10-28 English
Notice of Annual General Meeting/Proxy Form 22 pages 2.1MB
AGM Information
2021-10-28 English
Starpharma to present DEP at US Drug Delivery Conference 2 pages 209.3KB
Investor Presentation
2021-10-27 English
VIRALEZE distribution and supply to Vietnam 3 pages 225.8KB
Capital/Financing Update
2021-10-25 English
Notification regarding unquoted securities - SPL 7 pages 29.4KB
Share Issue/Capital Change
2021-10-24 English
VIRALEZE ADMENTA agreement - supplementary information 2 pages 206.6KB
Regulatory Filings
2021-10-11 English
VIRALEZE launch in ADMENTA Italia Group pharmacies in Italy 3 pages 439.5KB
Regulatory Filings
2021-10-07 English
2021 Annual General Meeting 1 page 196.8KB
AGM Information
2021-09-30 English
Notification of cessation of securities - SPL 4 pages 24.2KB
Share Issue/Capital Change
2021-09-30 English
Change in Director's Interest Notice - J Fairley 2 pages 200.8KB
Director's Dealing
2021-09-30 English
US patent issued for DEP cabazitaxel nanoparticle 3 pages 229.8KB
Regulatory Filings
2021-09-14 English
Application for quotation of securities - SPL 7 pages 29.1KB
Share Issue/Capital Change
2021-09-12 English
Change in Director's Interest Notice - Z Peach 2 pages 178.7KB
Director's Dealing
2021-08-30 English
Change in Director's Interest Notice - J Fairley 2 pages 197.8KB
Director's Dealing
2021-08-29 English
Change in Director's Interest Notice - L Cheng 2 pages 178.7KB
Director's Dealing
2021-08-26 English
Change in Director's Interest Notice - R Thomas 2 pages 180.3KB
Director's Dealing
2021-08-26 English
Starpharma annual report and full year financial results 99 pages 5.2MB
Annual Report
2021-08-25 English
Appendix 4G - Corporate Governance Statement 15 pages 412.7KB
Governance Information
2021-08-25 English
VIRALEZE Protects Against SARS-CoV-2 in Challenge Model 6 pages 352.0KB
Regulatory Filings
2021-08-22 English
VIRALEZE well tolerated in multiple dose clinical study 3 pages 219.8KB
Regulatory Filings
2021-08-16 English
Initial Director's Interest Notice 2 pages 237.5KB
Director's Dealing
2021-08-01 English
Quarterly Cashflow and Activities Report 7 pages 312.8KB
Interim / Quarterly Report
2021-07-29 English
Resignation of non-executive director 4 pages 351.9KB
Director's Dealing
2021-07-28 English
Lynda Cheng appointed as non-executive director 2 pages 196.6KB
Board/Management Information
2021-07-27 English
VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variant 4 pages 296.9KB
Regulatory Filings
2021-07-26 English
Starpharma to present DEP platform at CRS Annual Meeting 3 pages 197.3KB
Investor Presentation
2021-07-26 English
TGA infringement notices for alleged advertising 2 pages 200.6KB
Regulatory Filings
2021-07-04 English
Change in substantial holding 12 pages 6.7MB
Major Shareholding Notification
2021-07-01 English
Starpharma to present at Virtual Life Science Investor Forum 33 pages 6.3MB
Investor Presentation
2021-06-23 English
VIRALEZE UK Update 2 pages 196.9KB
Regulatory Filings
2021-06-20 English
VIRALEZE SPL7013 virucidal against multiple COVID variants 5 pages 502.3KB
Regulatory Filings
2021-06-17 English
VIRALEZE antiviral nasal spray registered for sale in India 3 pages 275.4KB
Regulatory Filings
2021-06-10 English
VIRALEZE SPL7013 highly active in UK variant of coronavirus 5 pages 515.7KB
Regulatory Filings
2021-05-31 English
VIRALEZE partners with Harlequins in the UK 5 pages 870.3KB
Regulatory Filings
2021-05-10 English
VIRALEZE launches in Europe 3 pages 224.5KB
Regulatory Filings
2021-05-05 English
Shareholder Newsletter 6 pages 1.2MB
Investor Presentation
2021-04-27 English
Quarterly Cashflow and Activities Report 7 pages 299.6KB
Interim / Quarterly Report
2021-04-26 English
Appendix 2A 14 pages 306.2KB
Share Issue/Capital Change
2021-04-08 English
VIRALEZE now launched by LloydsPharmacy in the UK 2 pages 233.3KB
Regulatory Filings
2021-03-29 English
VIRALEZE to be launched with LloydsPharmacy in the UK 4 pages 248.0KB
Regulatory Filings
2021-03-24 English
DEP HER2-lutetium outperforms in human breast cancer model 5 pages 259.6KB
Investor Presentation
2021-03-15 English
SPL7013 active against other pandemic coronaviruses 5 pages 429.4KB
Investor Presentation
2021-03-02 English
Interim Report and Half-Year Financial Results 21 pages 1.4MB
Interim / Quarterly Report
2021-02-24 English
VIRALEZE antiviral nasal spray registered in Europe 3 pages 232.4KB
Regulatory Filings
2021-02-22 English
Starpharma signs DEP ADC Research Agreement with MSD 2 pages 177.7KB
Regulatory Filings
2021-02-11 English
AZD0466 clinical DEP program global expansion 2 pages 61.3KB
Capital/Financing Update
2021-02-08 English
Change in substantial holding 11 pages 5.4MB
Regulatory Filings
2021-02-02 English
Quarterly Cashflow and Activities Report 7 pages 99.8KB
Interim / Quarterly Report
2021-01-28 English
Appendix 2A 14 pages 175.0KB
Share Issue/Capital Change
2021-01-26 English
Change in substantial holding 5 pages 185.4KB
Major Shareholding Notification
2021-01-17 English
Change in substantial holding 5 pages 175.1KB
Major Shareholding Notification
2021-01-17 English